Medaus Recalls M.I.C 25/50/50 Vials Due to Sterility Concerns
Medaus, Inc. is recalling M.I.C 25/50/50 vials because the product lacks assurance of sterility. The recall affects 2,000 mL in vials distributed in the U.S., Japan, and New Zealand.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II. According to the rubric, FDA Class II recalls involving significant injury or property damage reports, or in this case a critical sterility failure for an injectable product, are classified as Severe (Score 4).
Plain-English summary
Medaus, Inc. is recalling M.I.C 25/50/50 W/METHYL B12 1MG/PYRIDOXAL 50MG/ML (PF), 1ML Vials. The recall is being conducted because the product lacks assurance of sterility. The affected product consists of 2,000 mL in vials.
The recall covers Lot # 151223-63 with a best-use date of 05/26/16. The product was distributed in the U.S. Nationwide, Japan, and New Zealand.
Consumers and healthcare providers should stop using the affected product and contact Medaus, Inc. for further instructions or a refund.
The recalled product
- Product
- M.I.C 25/50/50 W/METHYL B12 1MG/PYRIDOXAL 50MG/ML (PF), 1ML Vials, MEDAUS PHARMACY
- Manufacturer
- Medaus, Inc.
- Category
- Drug — Injectable
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 151223-63
- BUD: 05/26/16
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 88 recalled by Medaus, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 88 products in this recall →Related recalls
Same manufacturer · Medaus, Inc.
See all →- SevereMedaus Recalls Testosterone Cypionate Vials Due to Sterility Concerns
FDA (Drugs) · 2016-07-20
- SevereMedaus Recalls Testosterone Cypionate Vials Due to Sterility Concerns
FDA (Drugs) · 2016-07-20
- SevereMedaus Recalls Taurine Vials Due to Lack of Sterility Assurance
FDA (Drugs) · 2016-07-20
- SevereMedaus Recalls Lipo-Injection Vials Due to Sterility Assurance Concerns
FDA (Drugs) · 2016-07-20
- SevereMedaus Recalls B-Complex Vials Due to Sterility Concerns
FDA (Drugs) · 2016-07-20
Same hazard · lack of sterility
See all →- SevereGentle Eyes Lubricant Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereClear Eyes Redness Relief Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereWalgreens Lubricant Eye Drops Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-09-30
- SevereClear Eyes Redness Relief Eye Drops Recalled for Sterility Assurance Issues
FDA (Drugs) · 2026-09-30
- HighRohto Cooling Eye Drops Recalled Due to Lack of Assurance of Sterility
FDA (Drugs) · 2026-07-29
Similar recalls
- SevereMedaus Recalls Pyridoxine HCL Due to Sterility Concerns
FDA (Drugs) · 2013-09-25
- SevereMedaus Recalls Taurine 50 mg/mL PF Due to Sterility Concerns
FDA (Drugs) · 2013-09-25
- SevereBella Pharmaceuticals Recalls MIC 25/50/50 Vials Due to Sterility Concerns
FDA (Drugs) · 2017-09-20
- SevereMedaus Recalls L-Glutathione Injection Due to Sterility Concerns
FDA (Drugs) · 2013-09-25
- SevereMedaus Recalls Magnesium Chloride Injection Due to Sterility Concerns
FDA (Drugs) · 2013-09-25
- SevereMedaus Recalls NA Ascorbate Injection Due to Sterility Concerns
FDA (Drugs) · 2013-09-25